Beta Bionics, Inc. (BBNX)

Beta Bionics Statistics

Total Valuation

Beta Bionics has a market cap or net worth of $1.28 billion. The enterprise value is $834.45 million.

Market Cap	1.28B
Enterprise Value	834.45M

Important Dates

The last earnings date was Tuesday, October 28, 2025, after market close.

Earnings Date	Oct 28, 2025
Ex-Dividend Date	n/a

Share Statistics

Beta Bionics has 43.47 million shares outstanding. The number of shares has increased by 401.79% in one year.

Current Share Class	44.02M
Shares Outstanding	43.47M
Shares Change (YoY)	+401.79%
Shares Change (QoQ)	+0.56%
Owned by Insiders (%)	3.67%
Owned by Institutions (%)	75.77%
Float	23.70M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	8.54
Forward PS	9.72
PB Ratio	3.62
P/TBV Ratio	3.58
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	9.42
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 10.64, with a Debt / Equity ratio of 0.03.

Current Ratio	10.64
Quick Ratio	9.46
Debt / Equity	0.03
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -47.52% and return on invested capital (ROIC) is -25.03%.

Return on Equity (ROE)	-47.52%
Return on Assets (ROA)	-20.08%
Return on Invested Capital (ROIC)	-25.03%
Return on Capital Employed (ROCE)	-22.52%
Revenue Per Employee	$301,259
Profits Per Employee	-$264,769
Employee Count	294
Asset Turnover	0.41
Inventory Turnover	2.54

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

Beta (5Y)	n/a
52-Week Price Change	n/a
50-Day Moving Average	21.44
200-Day Moving Average	n/a
Relative Strength Index (RSI)	75.84
Average Volume (20 Days)	594,395

Short Selling Information

The latest short interest is 4.17 million, so 9.59% of the outstanding shares have been sold short.

Short Interest	4.17M
Short Previous Month	6.38M
Short % of Shares Out	9.59%
Short % of Float	17.59%
Short Ratio (days to cover)	0.05

Income Statement

In the last 12 months, Beta Bionics had revenue of $88.57 million and -$77.84 million in losses. Loss per share was -$2.50.

Revenue	88.57M
Gross Profit	48.28M
Operating Income	-68.59M
Pretax Income	-77.84M
Net Income	-77.84M
EBITDA	-67.33M
EBIT	-68.59M
Loss Per Share	-$2.50

Balance Sheet

The company has $228.69 million in cash and $7.69 million in debt, giving a net cash position of $221.00 million or $5.08 per share.

Cash & Cash Equivalents	228.69M
Total Debt	7.69M
Net Cash	221.00M
Net Cash Per Share	$5.08
Equity (Book Value)	294.76M
Book Value Per Share	6.70
Working Capital	244.64M

Cash Flow

In the last 12 months, operating cash flow was -$56.58 million and capital expenditures -$3.96 million, giving a free cash flow of -$60.53 million.

Operating Cash Flow	-56.58M
Capital Expenditures	-3.96M
Free Cash Flow	-60.53M
FCF Per Share	-$1.39

Margins

Gross margin is 54.51%, with operating and profit margins of -77.45% and -87.89%.

Gross Margin	54.51%
Operating Margin	-77.45%
Pretax Margin	-87.89%
Profit Margin	-87.89%
EBITDA Margin	-76.02%
EBIT Margin	-77.45%
FCF Margin	n/a

Dividends & Yields

Beta Bionics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-401.79%
Shareholder Yield	-401.79%
Earnings Yield	-7.38%
FCF Yield	-5.74%

Analyst Forecast

The average price target for Beta Bionics is $26.64, which is -9.69% lower than the current price. The consensus rating is "Strong Buy".

Price Target	$26.64
Price Target Difference	-9.69%
Analyst Consensus	Strong Buy
Analyst Count	11
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	2